Generating Learnings In Multiple Sclerosis News Today : Breaking News, Live Updates & Top Stories | Vimarsana

New real-world data show MAVENCLAD (cladribine tablets) had lower annualised relapse rates and longer time to first relapse and time to switch than fingolimod, dimethyl fumarate and teriflunomide

United statesSouth australiaUnited kingdomHelmut butzkuevenMonash universityMerck pressEuropean commissionAmericas committee for treatmentCentral clinical schoolDepartment of neuroscienceEuropean unionResearch in multiple sclerosisAmericas committeeMultiple sclerosisGenerating learnings in multiple sclerosisCladribine tablets treating